By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to ending childhood cancer by driving targeted and innovative research, has officially announced the appointment of Mark Zafra to its Board of Directors. This strategic addition brings a unique blend of high-level corporate expertise and personal advocacy to the organization’s leadership. Zafra, who currently serves as the Chief Procurement Officer (CPO) at LiveRamp, is a seasoned executive with more than two decades of experience in global strategic sourcing, procurement, and supply chain management. His appointment comes at a critical juncture for the organization as it seeks to accelerate the development of safe and effective treatments for the thousands of children diagnosed with cancer each year.
The selection of Zafra highlights a growing trend among non-profit organizations to recruit top-tier corporate talent to help navigate complex operational landscapes and optimize resource allocation. At LiveRamp, Zafra is responsible for overseeing global strategic sourcing, purchasing, travel, and accounts payable, managing significant budgets and cross-functional teams. His career trajectory includes leadership roles at some of the world’s most prominent technology and financial firms, including Twitter, Allianz Fireman’s Fund, McKesson, Hewlett-Packard (HP), and Agilent Technologies. Throughout these tenures, Zafra has become known for spearheading large-scale transformation initiatives that emphasize innovation, operational efficiency, and measurable impact—skills that CureSearch intends to leverage to maximize its research funding and organizational reach.
A Synergy of Professional Excellence and Personal Mission
The appointment of Mark Zafra is particularly significant due to his personal history as a cancer survivor. This dual perspective—as a corporate leader and a survivor—aligns perfectly with CureSearch’s mission-driven approach. In the realm of pediatric oncology, the transition from laboratory discovery to clinical application is often hindered by a lack of funding and specialized expertise. By bringing in a Board member who understands the intricacies of the supply chain and strategic sourcing, CureSearch aims to bridge the "innovation gap" that frequently stalls the development of new pediatric therapies.
Zafra’s personal journey began 20 years ago when he received his first cancer diagnosis. Since then, he has become a vocal advocate for advancing cancer research, emphasizing the need for treatments that are not only effective in eradicating tumors but are also safe for the developing bodies of children. Unlike adult cancers, childhood cancers often require specialized protocols to prevent long-term side effects, such as organ damage or secondary cancers, which can manifest decades after treatment. Zafra’s commitment to this cause is further evidenced by his upcoming participation in the CureSearch Ultimate Hike in Jackson, Wyoming. This endurance event serves as a platform to raise critical funds and awareness for cutting-edge research, marking his two decades of survivorship through physical challenge and philanthropy.
The Landscape of Pediatric Oncology and the Role of CureSearch
To understand the impact of Zafra’s appointment, it is essential to consider the current state of childhood cancer research in the United States. According to data from the National Cancer Institute (NCI) and the American Cancer Society, approximately 15,000 children and adolescents under the age of 19 are diagnosed with cancer annually. While survival rates have improved significantly over the last 50 years—rising from less than 50% to over 80% for many types of cancer—the progress is uneven. Certain high-risk cancers, such as brainstem gliomas or metastatic sarcomas, still have very poor prognoses.
Furthermore, the "cost of cure" remains high. Statistics show that 60% of childhood cancer survivors will suffer from at least one chronic or even life-threatening health condition as a result of their treatment. CureSearch focuses specifically on these challenges, funding research that prioritizes "targeted" therapies. These therapies are designed to attack cancer cells specifically while sparing healthy tissue, thereby reducing the toxic burden on young patients.
The financial landscape for pediatric research is also notoriously difficult. Federal funding for cancer research often prioritizes adult cancers due to the higher volume of cases. Only a small fraction of the NCI’s annual budget is dedicated specifically to pediatric oncology. This creates a reliance on private non-profits like CureSearch to fund the early-stage "bench-to-bedside" research that pharmaceutical companies may find too risky or unprofitable to pursue independently. Zafra’s background in procurement and strategic sourcing will be instrumental in ensuring that every dollar raised by CureSearch is utilized with maximum efficiency, directing funds toward the most promising clinical trials and research projects.
Strategic Implications of Corporate Leadership in Non-Profits
The integration of a Chief Procurement Officer into a non-profit Board suggests a shift toward more rigorous operational standards within the charitable sector. Jared Brancazio, the Board Chair for CureSearch, noted that Zafra’s professional leadership is expected to help guide the organization’s work and accelerate its impact. From a strategic standpoint, Zafra’s expertise in vendor management and global sourcing can be applied to the way CureSearch manages its partnerships with academic institutions, medical centers, and biotechnology firms.
In the context of non-profit governance, the CPO role brings several key advantages:
- Cost Optimization: Ensuring that administrative and operational costs are minimized so that the majority of donations go directly to research.
- Risk Management: Navigating the complexities of research grants and long-term funding commitments.
- Scalability: Applying the growth strategies used at companies like Twitter and LiveRamp to expand CureSearch’s fundraising and advocacy programs.
- Data-Driven Decision Making: Using analytical frameworks to evaluate the success of various research initiatives and adjusting strategies accordingly.
Chronology of Engagement and Future Outlook
The timeline for Zafra’s integration into the CureSearch Board follows a period of significant growth for the organization. Over the past several years, CureSearch has refined its focus on the "CureSearch Acceleration Initiative," which targets the hurdles that prevent new drugs from reaching the clinic.
- Early 2000s: Mark Zafra begins his professional career in the tech sector while simultaneously navigating his first cancer diagnosis and recovery.
- 2010-2020: Zafra holds leadership roles at Agilent, HP, and McKesson, honing his skills in global supply chain management.
- 2021-Present: Zafra joins LiveRamp as CPO, overseeing a transformation in the company’s procurement and sourcing strategies.
- 2024: Zafra is officially appointed to the CureSearch Board of Directors.
- Upcoming: Zafra will participate in the Ultimate Hike in Jackson, WY, a 20+ mile trek designed to raise funds for the next generation of cancer treatments.
Looking ahead, the collaboration between Zafra and the existing Board members is expected to focus on expanding the CureSearch Catapult Awards. These awards are specifically designed to fund phase I or phase II clinical trials that have a high probability of reaching the market. By applying a "corporate" lens to these philanthropic investments, Zafra can help the Board identify projects with the strongest strategic viability and the highest potential for patient impact.
Official Responses and Organizational Vision
The leadership at CureSearch has expressed high confidence in the new appointment. Jared Brancazio emphasized that the organization is "honored to have him help guide our work." The sentiment reflects a broader organizational goal of diversifying the Board’s skill set to include more than just medical professionals and traditional philanthropists. By including a leader from the tech and data industry, CureSearch is positioning itself to better understand the role of big data and AI in modern oncology research.
Mark Zafra himself articulated a deep sense of responsibility in his new role. He stated that his advocacy is rooted in a desire to ensure that his personal experience with cancer can serve as a catalyst for positive change for others. His commitment to the Ultimate Hike further illustrates a "lead by example" philosophy, bridging the gap between high-level governance and grassroots fundraising.
Broader Impact on the Pediatric Cancer Community
The appointment of Mark Zafra to the CureSearch Board of Directors is more than just a personnel change; it is a signal of the evolving nature of medical advocacy. As the search for a cure becomes increasingly dependent on complex global networks of researchers, regulators, and donors, the need for sophisticated supply chain and procurement expertise becomes paramount.
For the families of the 43 children diagnosed with cancer every day in the United States, this appointment represents hope for more efficient research and faster access to life-saving drugs. By combining Zafra’s professional acumen with CureSearch’s established research infrastructure, the organization is better equipped to tackle the systemic barriers that have historically slowed progress in pediatric oncology. As Zafra prepares for his hike in the rugged terrain of Jackson, Wyoming, he carries with him the dual legacy of a survivor and the strategic vision of a corporate leader, both of which are now dedicated to the singular goal of ending childhood cancer.